When can real‐world data generate real‐world evidence?

Use of Real‐World Evidence in Neuroscience‐Related New Drug and Biologics License Applications for Novel Therapeutics

(2023) Bartholt Bloomfield‐Clagett et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Real-World Evidence — Where Are We Now?

(2022) John Concato et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020

(2021) Bhakti Arondekar et al.   CLINICAL CANCER RESEARCH

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?

(2021) Robert Flynn et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications

(2021) Christina A. Purpura et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Magic of Randomization versus the Myth of Real-World Evidence

(2020) Rory Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of real-world data for new drug applications and line extensions

(2020) Winona R. Bolislis et al.   CLINICAL THERAPEUTICS

Randomized, observational, interventional, and real‐world—What's in a name?

(2020) John Concato et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

(2019) Suparna Wedam et al.   CLINICAL CANCER RESEARCH